CN110663790A - 一种具有保肝功能的云南白灵芝保健茶及其制备方法 - Google Patents
一种具有保肝功能的云南白灵芝保健茶及其制备方法 Download PDFInfo
- Publication number
- CN110663790A CN110663790A CN201911092938.XA CN201911092938A CN110663790A CN 110663790 A CN110663790 A CN 110663790A CN 201911092938 A CN201911092938 A CN 201911092938A CN 110663790 A CN110663790 A CN 110663790A
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- protection function
- health
- yunnan white
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000222336 Ganoderma Species 0.000 title claims abstract description 34
- 210000004185 liver Anatomy 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 241001122767 Theaceae Species 0.000 title description 31
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 42
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 238000001914 filtration Methods 0.000 claims abstract description 14
- 238000002156 mixing Methods 0.000 claims abstract description 13
- 241000212941 Glehnia Species 0.000 claims abstract description 10
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 10
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 238000004140 cleaning Methods 0.000 claims abstract description 7
- 230000001954 sterilising effect Effects 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 6
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 5
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 5
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 5
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 5
- 244000269722 Thea sinensis Species 0.000 claims abstract 12
- 239000000287 crude extract Substances 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 7
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 claims description 5
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 3
- 235000020990 white meat Nutrition 0.000 claims description 3
- 241000640636 Ganoderma leucocontextum Species 0.000 claims description 2
- 239000008213 purified water Substances 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 230000035622 drinking Effects 0.000 abstract description 5
- 239000003205 fragrance Substances 0.000 abstract description 5
- 235000019640 taste Nutrition 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000006870 function Effects 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 6
- 108010082126 Alanine transaminase Proteins 0.000 description 6
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 6
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 6
- 206010067125 Liver injury Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 231100000439 acute liver injury Toxicity 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical group COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种具有保肝功能的云南白灵芝保健茶及其制备方法,包括:1)分别将5‑10重量份的灵芝、5‑10重量份的葛根、3‑5重量份的北沙参、1‑3重量份的炙甘草进行净选、粉碎;2)将上述原料混合后加入700‑1000重量份的水煎煮1‑2小时,经过滤,干燥后,加入50‑500重量份的水,混匀,静置,过滤,灭菌后制成;该方法操作简便,制成的云南白灵芝保健茶具灵芝的特殊香气,口感柔和,品质稳定,没有毒副作用,适于长期饮用,具有良好的保肝功能。
Description
技术领域
本发明涉及保健食品领域,尤其是一种具有保肝功能的云南白灵芝保健茶及其制备方法。
背景技术
肝脏是人体最重要的代谢器官,其一个至关重要的的功能就是解毒功能,能将外来的或体内代谢产生的有毒物质变为无毒或溶解度大的物质,随胆汁或尿液排出体外。随着人们生活水平的不断提高,生活节奏的不断加快,工作压力越来越大、饮食不规律不健康、药物滥用、饮酒过度等对肝脏造成的负担也越来大,最终形成对肝脏不可逆的损伤,导致肝纤维化,甚至肝硬化及肝癌的发生。
目前临床上用于治疗肝损伤的药物较少,且大都疗效有限,副作用高,不能满足人们的实际需要。灵芝作为药物在我国已有2000年的历史,被历代医药家视为滋补强壮、扶正固本的珍品。在我国最早的药学专著《神农本草经》将灵芝列为上品,有紫、赤、青、黄、白、黑六种,被称之为:“上上之药,方中妙品”。
云南白灵芝属于灵芝属(Ganoderma)中的罕见低温型种类,自然生长在海拔2500米以上区域,菌盖和菌柄的质地均匀、肉质白色。前期研究结果表明,云南白灵芝有效成分含量远高于赤芝,云南白灵芝较赤芝具有更显著的保护肝脏作用,能增强人体免疫功能,在对化学性肝损伤及酒精性肝损伤的修复方面具有良好的功效。因此,开发一种具有保肝功能的云南白灵芝保健茶及其制备方法,将其应用于保健食品领域具有重要的意义。
发明内容
本发明所要解决的技术问题是提供一种操作简便,制成的云南白灵芝保健茶具灵芝的特殊香气,口感柔和,品质稳定,没有毒副作用,适于长期饮用,具有良好保肝功能的云南白灵芝保健茶。
为解决上述技术问题,本发明的技术方案是:
1、一种具有保肝功能的云南白灵芝保健茶,包括下列重量份的原料配制而成:灵芝(5-10份),葛根(5-10份),北沙参(3-5份),炙甘草(1-3份);配方中所用的灵芝品种为云南省农业科学院培育的栽培品种:云南白灵芝 (学名: 白肉灵芝 Ganoderma leucocontextum)。
2、本发明还提供一种制备上述具有保肝功能的云南白灵芝保健茶的方法:
1)将5-10重量份的灵芝、5-10重量份的葛根、3-5重量份的北沙参、1-3重量份的炙甘草净选,混合后,加入700-1000重量份的水煎煮1-2小时,自然冷却至常温,过滤,弃滤渣,得到粗提液;
2)将上述粗提液干燥后,加入50-500重量份的水,混匀,静置,将所得溶液过滤,滤液在90-110℃温度下灭菌2-10分钟,灌装后即得所述具有保肝功能的云南白灵芝保健茶。
作为对上述技术方案的改进,所述步骤1)各重量份原料净选后,需按比例混合均匀后再加水煎煮,制成粗提液。
作为对上述技术方案的改进,所述步骤2)得到的粗提液需干燥后再加水复溶过滤,滤液经灭菌后,立即灌装至特定包装中,即得所述具有保肝功能的云南白灵芝保健茶。
作为优选的技术方案,所述包装的形式为袋装或者瓶装。
作为优选的技术方案,所述水为纯净水。
本发明的有益效果在于:
1)本发明的制备方法操作简便、产品质量稳定、易于工业化生产;
2)本发明所采用的灵芝品种为云南白灵芝,是一种稳定性强,安全性好,功效显著的品种;
3)本发明制备的云南白灵芝保健茶具有良好的保肝功能。
具体实施方式
下面通过具体实施例对本发明作进一步详细说明,但本发明的保护范围不局限于所述内容,凡基于本发明上述内容所实现的技术均属于本发明的范围。实施例中方法如无特殊说明均采用常规方法,使用试剂如无特殊说明,均为常规市售试剂或采用常规方法配置的试剂。
实施例1:云南白灵芝保健茶的制备,一种具有保肝功能的云南白灵芝保健茶,其原料配方按重量份计为:灵芝50g,葛根50g,北沙参30g,炙甘草10g,所述的云南白灵芝保健茶的制备方法,包括以下步骤:
1)将50g的灵芝、50g葛根、30g的北沙参、10g的炙甘草净选,混合后,加入700 mL的水煎煮1小时,自然冷却至常温,过滤,弃滤渣,得到粗提液;
2)将粗提液喷雾干燥,得提取物(含水量≤17%)后,加入500mL的水,混匀,静置,将所得溶液过滤,滤液在90℃温度下灭菌10分钟,即得所述具有保肝功能的云南白灵芝保健茶。
产品具有灵芝的特殊香气,口感清爽,微苦回甘,适于长期饮用。
实施例2:云南白灵芝保健茶的制备,一种具有保肝功能的云南白灵芝保健茶,其原料配方按重量份计为:灵芝100g,葛根100g,北沙参50g,炙甘草30g,所述的云南白灵芝保健茶的制备方法,包括以下步骤:
1)将100g的灵芝、100g葛根、50g的北沙参、30g的炙甘草净选,混合后,加入1000 mL的水煎煮2小时,自然冷却至常温,过滤,弃滤渣,得到粗提液;
2)将粗提液烘干,得提取物(含水量≤17%)后,加入500mL的水,混匀,静置,将所得溶液过滤,滤液在110℃温度下灭菌2分钟,即得所述具有保肝功能的云南白灵芝保健茶。
产品具有灵芝的特殊香气,口感清爽,微苦回甘,适于长期饮用。
实施例3:云南白灵芝保健茶(浓缩)的制备,一种具有保肝功能的云南白灵芝保健茶(浓缩),其原料配方按重量份计为:灵芝100g,葛根100g,北沙参50g,炙甘草30g所述的云南白灵芝保健茶(浓缩)的制备方法,包括以下步骤:
1)将100g的灵芝、100g葛根、50g的北沙参、30g的炙甘草净选,混合后,加入1000 mL的水煎煮2小时,自然冷却至常温,过滤,弃滤渣,得到粗提液;
2)将粗提液真空干燥,得提取物(含水量≤17%)后,加入50mL的水,混匀,静置,将所得溶液过滤,滤液在90℃温度下灭菌10分钟,即得所述具有保肝功能的云南白灵芝保健茶(浓缩)。
产品具有浓郁的灵芝香气,口感醇厚,苦味,无毒副作用。
实施例4:云南白灵芝保健茶的保肝功能试验,将72只SPF级昆明种小鼠(体重20±2 g,雌雄各半)小鼠适应性喂养7天,分为6组,每组12只,分别为空白组、模型组、联苯双酯组(100 mg/kg)、云南白灵芝保健茶组(低、中、高三个浓度)。云南白灵芝保健茶组由实施例3制备。各给药组每天灌胃给药1次,连续给药7天,空白组及模型组每天给予等量蒸馏水;末次给药后2 h,以0.1 mL/10 g剂量腹腔注射0.4% CCl4橄榄油溶液,禁食不禁水16h后,小鼠眼眶取血;脱臼处死小鼠,取肝脏,经液氮处理后,冻存于-80℃冰箱。取全血于装有0.109mol/L柠檬酸三钠即抗凝剂的离心管中,以抗凝剂: 全血为1: 9的比例收集全血,在4℃下、3500 r/min离心15 min,收集上清,用于测定谷丙转氨酶(ALT)、谷草转氨酶(AST)。
肝损伤的程度由血清中ALT、AST酶活力评价,结果见表1。与空白组相比,模型组ALT、AST酶活力显著升高,分别是66.09±7.42 U/L、72.04±5.31 U/L;表明CCl4致小鼠急性肝损伤模型制作成功。给药后,云南白灵芝保健茶中浓度与高浓度组相较于模型组ALT、AST酶活力均有所下降,能显著地降低ALT、AST酶活力。结果表明云南白灵芝保健茶能显著降低CCl4对肝脏细胞的损害,具有良好的保肝功能。
表 1 云南白灵芝保健茶对CCl4致小鼠急性肝损伤的影响
实施例5:云南白灵芝保健茶的小鼠急性经口毒性试验,为了解云南白灵芝保健茶的急性毒性,本试验采用SPF级昆明种小鼠40只,进行急性经口毒性试验,将动物随机分为对照组和云南白灵芝保健茶(低、中、高)四个组(由实施例3制备),每组10只,雌雄各半,分别24小时内3次经口灌胃给予蒸馏水(0.2ml/10g)及云南白灵芝保健茶(1g/kg.bw, 2g/kg.bw, 5g/kg.bw),给药后连续饲养观察14天,结果见表2。
表2 云南白灵芝保健茶急性经口毒理试验
结果显示:1、一般状况及症状体征:灌胃给予受试物后,受试物组大部分小鼠一般状态良好,活动自如,进食、饮水正常、皮毛光泽、精神状态良好,未出现明显毒副反应和动物死亡;2、体重变化:小鼠在给药后,各时间段体重与给药前相比均有增长(P<0.01),给药后第4天、第7天、第11天、第14天体重增长幅度均和对照组相当(P>0.05);3、系统解剖肉眼观察:试验结束全部动物存活,解剖肉眼观察,所有动物心、肝、脾、肺、肾等主要脏器、器官表面光滑、色泽质地正常,胃、肠粘膜未见充血、出血等异常改变。
对按本发明制得的云南白灵芝保健茶,进行昆明种小鼠急性经口毒性试验;给药后连续观察14天,动物体重增长,试验动物全部存活,无明显急性毒性危害。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (7)
1.一种具有保肝功能的云南白灵芝保健茶及其制备方法,其特征在于,包括下列重量份的原料配制而成:灵芝(5-10份),葛根(5-10份),北沙参(3-5份),炙甘草(1-3份)。
2.如权利要求1所述的具有保肝功能的云南白灵芝保健茶,其特征在于,配方中所用的灵芝品种为云南省农业科学院培育的栽培品种:云南白灵芝 (学名: 白肉灵芝 Ganoderma leucocontextum)。
3.一种制备具有保肝功能的云南白灵芝保健茶的方法,其特征在于,包括步骤:
1)将5-10重量份的灵芝、5-10重量份的葛根、3-5重量份的北沙参、1-3重量份的炙甘草净选,混合后,加入700-1000重量份的水煎煮1-2小时,自然冷却至常温,过滤,弃滤渣,得到粗提液;
2)将上述粗提液干燥后,加入50-500重量份的水,混匀,静置,将所得溶液过滤,滤液在90-110℃温度下灭菌2-10分钟,灌装后即得所述具有保肝功能的云南白灵芝保健茶。
4.如权利要求3所述的制备具有保肝功能的云南白灵芝保健茶的方法,其特征在于:所述步骤1)各重量份原料净选后,需按比例混合均匀后再加水煎煮,得到粗提液。
5.如权利要求3所述的制备具有保肝功能的云南白灵芝保健茶的方法,其特征在于:所述步骤2)得到的粗提液需干燥后再加水复溶过滤,滤液经灭菌后,立即灌装至特定包装中即得所述具有保肝功能的云南白灵芝茶。
6.如权利要求3所述的制备具有保肝功能的云南白灵芝保健茶的方法,其特征在于:所述水为纯净水。
7.如权利要求3所述的制备具有保肝功能的云南白灵芝保健茶,其特征在于:所述包装的形式为袋装或者瓶装。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911092938.XA CN110663790A (zh) | 2019-11-13 | 2019-11-13 | 一种具有保肝功能的云南白灵芝保健茶及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911092938.XA CN110663790A (zh) | 2019-11-13 | 2019-11-13 | 一种具有保肝功能的云南白灵芝保健茶及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110663790A true CN110663790A (zh) | 2020-01-10 |
Family
ID=69086861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911092938.XA Pending CN110663790A (zh) | 2019-11-13 | 2019-11-13 | 一种具有保肝功能的云南白灵芝保健茶及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110663790A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101564419A (zh) * | 2008-04-23 | 2009-10-28 | 北京卓越同创药物研究院 | 一种保肝药物组合物 |
CN103005594A (zh) * | 2012-12-18 | 2013-04-03 | 段海庆 | 一种饮料 |
-
2019
- 2019-11-13 CN CN201911092938.XA patent/CN110663790A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101564419A (zh) * | 2008-04-23 | 2009-10-28 | 北京卓越同创药物研究院 | 一种保肝药物组合物 |
CN103005594A (zh) * | 2012-12-18 | 2013-04-03 | 段海庆 | 一种饮料 |
Non-Patent Citations (1)
Title |
---|
郭岁洋: "《四百味药性歌括解》", 30 June 2019, 甘肃科学技术出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100372561B1 (ko) | 천연 생약제 추출물을 포함하는 숙취해소용 조성물 및이를 유효성분으로 함유하는 건강보조식품 | |
CN106260409B (zh) | 一种护肝醒酒软糖及其制备工艺 | |
CN111374297A (zh) | 一种复合食盐及其制备方法 | |
CN103168883A (zh) | 可增强免疫力、抗病原微生物、抗病毒的茶饮料颗粒剂及其制备方法 | |
WO2021114586A1 (zh) | 一种具有提高免疫力功能的组合物及其制备方法和应用 | |
KR100552398B1 (ko) | 작두콩 추출물을 포함하는 숙취해소용 음료조성물 | |
CN105664140A (zh) | 一种糖肽组合物及其制备方法和用途 | |
KR101199961B1 (ko) | 방풍통성산 또는 이의 유산균 발효물을 포함하는 골다공증 예방 또는 치료용 조성물 | |
CN107836620A (zh) | 一种养生固体饮料及其制备方法 | |
WO2010076920A1 (ko) | 상황버섯과 동충하초를 포함하는 항암용 건강식품 | |
CN110663790A (zh) | 一种具有保肝功能的云南白灵芝保健茶及其制备方法 | |
KR101023487B1 (ko) | 오미자, 황금 및 해동피의 혼합 생약재 추출물을 유효성분으로 포함하는 관절염 예방 또는 치료용 조성물 | |
KR101795261B1 (ko) | 구기자를 포함하는 간 기능 개선용 한방조성물 및 그 제조방법 | |
JPH0767576A (ja) | 菌糸体健康食材 | |
WO2018052171A1 (ko) | 율무 추출물을 포함하는 위암 치료용 조성물과 그 추출방법 | |
KR101968891B1 (ko) | 멀꿀 열매 추출물을 유효성분으로 포함하는 혈중알콜농도 저감 촉진용 조성물 | |
CN110237116A (zh) | 一种降三高组合物及其制备方法 | |
WO2005094858A1 (ja) | 抗糖尿病用組成物 | |
JP2618286B2 (ja) | 降圧酵母製剤及びその製造法 | |
CN109662317A (zh) | 一种用于肠胃调理养生的组合物及其使用方法 | |
KR20030079289A (ko) | 숙취해소용 탄산음료 제조방법 및 그 조성물. | |
KR20200076185A (ko) | 엉겅퀴 및 양파를 포함하는 혼합물을 함유하는 간질환의 개선, 예방 또는 치료용 조성물 | |
CN108938749B (zh) | 一种药物组合物及其制备方法和应用 | |
CN116036191A (zh) | 一种补气血的中药组合物及其制备方法 | |
CN108208781A (zh) | 一种修复肝损伤、增强免疫力的蛹虫草组合物及制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200110 |
|
WD01 | Invention patent application deemed withdrawn after publication |